Научно-практическая ревматология

Расширенный поиск

Эффективность и переносимость таблетированной формы ибандроната при лечении постменопаузального остеопороза

Полный текст:

Список литературы

1. <div><p>Беневоленская Л.И. Бнсфосфонаты в терапии и профилактике остеопороза. Росс, ревматол., 1998, 2, 2-9</p><p>Беневоленская Л.И. Бнсфосфонаты и остеопорозю. Рук. по остеопорозу (под ред. Проф. Л.И.Беневоленской). БИНОМ, М., 2003, 196-216</p><p>Bauss F., Kling L., Sponer G. Comparison of continuous and ciclical administration of ibandronate on bone mass in ovariec- tomized rats. Bone Miner.Res,, 1996, 11 (suppl. 1), S336</p><p>Bidstrup B., Ise J., Huss H. et al. Total dose, and not dosing frequency, determines treatment response to ibandronate. Osteopor. Int. 2000, ll(supl.l), S26</p><p>Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J.Bone Miner.Res., 2004, 19, 1241-1249</p><p>Cooper C., Emkey R.D., McDonald R.H. et al. Efficacy and safely of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J.CIin. Endocrinol. Metab., 2003, 88, 4609-15</p><p>Delmas P.D., R.R. Recker, Chesnut HI C.H. el al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteopor. Int., 2004, 15, 792-798</p><p>Lalla S., Hothorn L.A., Hagg N. et al. Lifelong of high doses of ibandronate increases bone mass and maintains bone quality in lumbar vertebrae in rats. Osteopor. Int., 1998, 8, 97-103</p><p>Ravn P., Clemmesen B., Riis B.J., Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone, 1996, 19, 527-533</p><p>Ravn P., Christiansen C., Baumann М.,Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment : Prediction of bone mass changes during treatment. Bone, 1998, 22, 559-564</p><p>Riis B.J., Ise J., von Stein T. et al. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J.Bone Miner.Res., 2001,16, 1871-1878</p><p>Munbauers R.C., Bauss F., Schenk R. et al. Ibandronate, a potent new bisphosphonate to inhibit bone resorption. J.Bone Miner.Res., 1991,6, 1003-1011</p></div><br />


Для цитирования:

Toroplsova N.V., Benevolenskaya L.L., Nikilinskaya O.A., Demin N.V. Эффективность и переносимость таблетированной формы ибандроната при лечении постменопаузального остеопороза. Научно-практическая ревматология. 2005;43(5):44-47.

For citation:

Toroplsova N.V., Benevolenskaya L.L., Nikilinskaya O.A., Demin N.V. Efficacy and safety of ibandronat tablets for treatment of postmenopausal osteoporosis. Rheumatology Science and Practice. 2005;43(5):44-47. (In Russ.)

Просмотров: 669

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)